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Fifty-seven patients with chronic hepatitis B, hepatitis B
virus (HBV) e antigen (HBeAg) and HBV DNA positivity,
and aminotransferase elevation despite a previous course of
any type of adequate interferon alfa (IFN-a) therapy were
included in a multicenter prospective randomized con-
trolled trial. The objective of the study was to compare a
second course of IFN-a therapy (9 million units [MU] of
IFN-a-2a, Roferon-A, thrice weekly for 6 months) versus no
therapy in terms of loss of HBV DNA and HBeAg. At the end
of the study, a sustained clearance of HBV DNA and HBeAg
was observed in 9 of the 27 (33.3%) patients who had
received retreatment with IFN-a compared with 3/30 (10%)
patients who spontaneously cleared these markers in the
untreated control group (x2 5 4.66, P 5 .031; odds ratio:
4.5, 95%; confidence interval: 1.1-18.9). None of the re-
sponders lost HBsAg. Patients retreated with IFN-a were
more likely to have biochemical remission in association
with HBV clearance (5/27, 18.5%) compared with untreated
patients (1/30, 3.3%; Fisher’s exact test P 5 .09 ). Histologi-
cal improvement in the liver necroinflammatory activity
was observed among sustained responders to IFN-a retreat-
ment, consisting of regression of the portal and periportal
inflammation and of the piecemeal necrosis; there was no
change in the degree of liver fibrosis. Side effects were
similar to those previously reported during IFN-a treat-
ment; these were mild and reversible on IFN-a discontinua-
tion. None of the baseline features were associated with
response by Cox’s regression analysis. In summary, viremic
patients with chronic HBeAg-positive hepatitis may experi-
ence disease remission following retreatment with IFN-a.
Thus, retreatment with IFN-a may be considered a therapeu-
tic option. (HEPATOLOGY 1999;29:277-282.)
It has been proven that chronic hepatitis B virus (HBV)
infection may have a progressive course ending in liver
cirrhosis or hepatocellular carcinoma.1,2 Interferon alfa
(IFN-a) has been used as therapy for this disease, leading to a
sustained loss of HBV DNA and hepatitis B e antigen (HBeAg)
(and seroconversion to anti-HBe) and biochemical improve-
ment (normalization of alanine transaminase [ALT] values)
in around 25% to 40% of the treated patients.2-10 However, the
remaining patients do not achieve a response, including those
patients who relapse after achieving an initial response and
patients who do not respond. These patients may potentially
benefit from another cycle of IFN-a treatment.
Attempts in pilot studies of retreatment with IFN-a for
previous nonresponders provided no definite conclusions on
its possible efficacy in chronic HBV.11 No controlled trial
evaluating the benefits of retreatment of chronic HBV with
IFN-a has been published. The objective of our study has
been to determine whether a second course of IFN-a, given
during 6 months, is safe and acceptable, and whether it
results in a significantly higher treatment response (loss of
HBeAg and HBV DNA) than no treatment in previously
nonresponder patients with chronic HBV.
PATIENTS AND METHODS
Study Design. This study was designed as a multicenter (see
Appendix) randomized controlled trial in patients who failed to
respond to a previous cycle of IFN-a. Assuming that patients with
no treatment show a 5% response, and patients with retreatment
25% (a 20% difference),7 a total number of 145 patients was needed
to detect a significant difference at the 5% level with a power of 80%,
taking into account a possible 25% drop-out rate during the study.
The inclusion period started in April 1992 and ended in December
1996. At that time, 62 patients who were HBeAg– and HBV
DNA–positive in serum with abnormal ALT values (documented at
least 3 times within the 6 months screening period) and a chronic
HBV12 documented in a liver biopsy obtained within 1 year before
inclusion had been enrolled. The patients should have undergone a
previous treatment of only one course of any type of IFN-a
treatment (recombinant or lymphoblastoid) for at least 12 weeks
with a minimum of 13.5 million units (MU) per week8,13; at the end
of the first IFN-a cycle ( at least 6 months before enrollment in this
study) patients should have been HBeAg–positive.
The following patient exclusion criteria were used: (1) evidence
of any other type of liver disease, i.e., anti-hepatitis C virus or
anti-hepatitis D virus positive, alcohol, ascites, bleeding varices, or
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hepatic encephalopathy; (2) immunocompromised patient (anti-
HIV–positive, transplantation, hemodialysis, etc.); (3) active intrave-
nous drug use or presence of significant medical illness that might
interfere with this trial; (4) women with positive pregnancy test or
not practicing an adequate birth control method; (5) patients with
neuropsychiatric disorders including seizures; (6) low levels of
hemoglobin (, 6 mmol/L), white blood cell (, 3 3 109/L) or
platelet (, 70 3 109/L) counts; (7) class B or C cirrhosis according
to the Child Pugh classification; and (8) previous treatment other
than IFN-a in the preceding 12 months.
The dose and treatment duration were selected because better
results are obtained with doses of 4.5 to 18 MU 3 times per week
during 12 to 24 weeks6,8,14 and with prolongation of the treatment
period.13 For these reasons, a 6-month treatment course was chosen
with a dose of 9 MU of recombinant IFN (rIFN)-a-2a (Roferon-A, F.
Hoffmann-La Roche, Basel, Switzerland), subcutaneously, 3 times
per week. Eligible patients were randomized to treatment or
observation. Patients in the control group were observed for the
same period, and both groups were studied further for another
6-month period after completing treatment or observation. This
study was approved by the Eurohep and local Ethics Committees
and conducted in accordance with the guidelines of ‘‘Good Clinical
Practice,’’ which underwrites the principles of the declaration of
Helsinki on human experimentation. Written informed consent
according to local legal requirements was obtained from each patient
participating in this study.
Laboratory Tests. HBsAg, HBeAg, anti-HBe, and anti-hepatitis D
virus were determined by commercial assays (Abbott Labs., North
Chicago, IL); anti-hepatitis C virus was tested by EIA (Ortho).
Biochemical and hematological parameters were measured by stan-
dard methods; a liver ultrasound was also performed. During and
after therapy, the patients (treated and untreated) were examined at
every visit. Blood was drawn every month and locally analyzed for
HBeAg, ALT, leukocytes, and platelets. Aliquots of serum samples
were stored at 220°C and shipped frozen for central examination of
the virus load in one center (Madrid, Spain). HBV DNA was
quantitated by a liquid hybridization assay (Abbott) with a detection
limit of 1.7 pg/mL.15 For statistical analysis, the detection limit was
assigned to samples with undetectable levels.
Efficacy and Safety Criteria. Response was defined as the loss of
serum HBV DNA and HBeAg at the end of treatment (6 months). At
the end of follow-up (12 months), those patients with a persisting
response according to the above criteria were defined as sustained
responders whereas those patients who lose any or all response
criteria were considered as relapsers; patients who did not achieve
the response criteria were considered nonresponders. A second liver
biopsy was obtained in 34 patients who agreed to undergo this
procedure one year after the start of treatment or the no-treatment
period. Changes in liver histology between the baseline and fol-
low-up biopsies were reviewed for each individual patient centrally
and blindly by the same pathologist. Safety assessments were done
according to the World Health Organization classification of toxicity.
Paracetamol (up to 4 3 500 mg) was given to minimize side-effects
of IFN-a. Patients were withdrawn from the analysis of intention-to-
treat wherever the eligibility criteria had not been complied with,
thus influencing the evaluation of efficacy. All patients who received
test medication and had at least one postbaseline assessment were
included in the safety analysis.
Statistical Analysis. The similarity of clinical and laboratory charac-
teristics of the 2 groups at randomization was assessed using the x2
and Mann-Whitney’s tests. All the data were analyzed on an
intention-to-treat basis. The kinetics of HBV DNA concentrations
were studied by Wilcoxon’s signed rank test or Mann-Whitney’s test
in paired or independent samples, respectively. The Kaplan-Meier
analysis was performed to assess the difference in the occurrence of
HBV DNA and HBeAg clearance between IFN-a retreatment and no
treatment. The time of these events was estimated at the midpoint
between the last positive value and the first negative value. The
association of baseline features with treatment response was evalu-
ated by Cox’s regression analysis to estimate relative risks as odds
ratios and confidence intervals. All P-values reported are two-tailed.
Statistical analysis was performed using the SPSS program (v7.5)
(SPSS Inc., Chicago, IL).
RESULTS
Of the 62 patients randomized, 5 were excluded (3 in the
retreatment and 2 in the untreated control group, respec-
tively) because of protocol violation that potentially could
bias the study (e.g., negative HBV DNA in 4, normal ALT
values in 1). Thus, 57 patients started the protocol, 27 in the
IFN-a-2a retreatment group, and 30 in the untreated control
group. There were no differences in the baseline demograph-
ics between study groups (Table 1).
During IFN-a retreatment, serum HBV DNA levels de-
creased with respect to the basal values, and the difference
was significant compared with the control group at the end of
therapy (P 5 .029). Also, at the end of the follow-up period,
the serum HBV DNA concentration was significantly lower
than the basal sample in treated patients (P , .01) but not in
controls (Fig. 1). At the end of retreatment, or the observa-
tion period for untreated controls, there was a greater,
although not statistically significant, disappearance of HBV
DNA in the retreated patients (7/27, 26%) compared with the
controls (3/30, 10%). Serum HBV DNA re-appeared in 2
retreated patients but became negative in 7, as well as in 7
untreated controls. Thus, HBV DNA clearance was higher,
but not significantly, in the retreated patients (12/27, 44%)
compared with the untreated controls (10/30, 33%) at the end
of the study.
Loss of HBeAg was greater in the retreatment group at the
end of therapy (6/27, 22%) compared with the control group
(3/30, 10%), although the difference was not statistically
significant. However, at the end of the follow-up, loss of
HBeAg was significantly more frequent in the treated patients
(11/27, 41%) than in the untreated controls (5/30, 17%)
(x2 5 4.08, P 5 .043).
TABLE 1. Baseline Demographics of the Patients in Groups as Established
by Randomization
IFN-a Retreatment
(n 5 27)
Untreated Control
(n 5 30) P
Age (yr)* 31 (18-63) 33 (18-61) 0.64
Gender (M/F) 26/1 25/5 0.11
Duration of HBsAg positivity
(mo)* 50 (24-156) 48 (24-144) 0.81
ALT† 2.7 (1.1-12) 2.5 (1.1-15) 0.54
HBV DNA in serum (pg/mL)* 82.0 (1.72-636) 50.7 (2.28-920) 0.37
Liver histology (chronic hepati-
tis): minimal/mild/moder-
ate/NA 8/13/1/5 8/17/2/3 0.75
Liver cirrhosis: no. (%) 3 (11) 2 (7) 0.90
Previous IFN (total dose in
MU)* 600 (180-1080) 696 (234-2592) 0.40
No. (%) given ,432 MU IFN‡ 6 (22) 10 (33) 0.35
No. rIFN-a-2a/rIFN-a-2b/IFN-
a-n1 10/14/3 14/15/1 0.46
Abbreviations: NA, not available or inadequate for evaluation.
*Results are expressed as median (range) and compared by x2 or
Mann-Whitney tests.
†Median (range) of the ratio of ALT values with respect to the upper limit
of normal range values.
‡Corresponds to at least 9 MU thrice weekly for 16 weeks.
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A complete virological response at the end of the study
(e.g., sustained clearance of HBV DNA and HBeAg) was
observed in 9 of the 27 (33%) patients who had received
retreatment with IFN-a, which was statistically significantly
higher compared with 3/30 (10%) patients who spontane-
ously cleared these markers in the untreated control group
(x2 5 4.66, P 5 .031; odds ratio: 4.5, 95%; confidence
interval: 1.1-18.9). Figure 2 shows the Kaplan-Meier estimate
of the combined HBV DNA and HBeAg clearance during the
initial 6 months retreatment or observation period in the
control group and the 6 months of follow-up. Seroconversion
from HBeAg to anti-HBe was found in 6 of those 9 responders
to retreatment (after 6 months in 3 and after 12 months in 3
other patients) and in the 3 untreated controls with spontane-
ous HBeAg clearance (after the initial 6 months in 2)
(retreatment vs. control: 27% vs. 10%; P not significant).
None of the patients lost HBsAg, irrespective of the study
group.
Four patients experienced a flare in ALT values (. 2.5 3
baseline ALT value) preceding or at the time of HBV DNA
clearance irrespective of the retreatment or control group; the
flare ranged from 2.74- to 14.9-fold the baseline value. At the
end of the study, ALT levels decreased significantly (P , .05)
compared with the baseline in either the sustained respond-
ers to retreatment or control patients with HBV clearance.
ALT normalization was observed in 6 retreated patients and 5
controls. Of these patients with normal ALT, 5/6 (83%) were
responders to retreatment with IFN-a compared with 1/5
(20%) untreated patients (Fisher’s exact test P 5 .08; not
significant). Thus, retreated patients were more likely to clear
HBV and have normal ALT values (5/27, 18.5%) compared
with the untreated controls (1/30 , 3.3%) (Fisher’s exact test
P 5 .09; not significant ).
Histological scoring was performed in 49 initial liver
biopsies (22 in the retreatment and 27 in the untreated
control group). No biopsy was available from 7 patients and it
was inadequate for evaluation in 1. There were no significant
pretreatment or post-treatment differences in the necroinflam-
mation (Fig. 3) and fibrosis scores among groups. Paired liver
biopsies were evaluable in 30 patients (15 in each study
group), including 7/9 sustained responders to retreatment,
and the 3 untreated controls who cleared HBV spontaneously.
A histological improvement in the necroinflammatory activ-
ity was observed among sustained responders to IFN-a
retreatment as well as in controls with spontaneous HBV
FIG. 1. Serum HBV DNA levels (expressed as the median and the 25th
through 75th percentile) throughout the study in the retreatment (j) and
control (h) groups: at the start, at therapy cessation, or the 6-month
observation period and at the end of follow-up (12 months). *P 5 .029
retreatment vs. control. **P , .01 with respect to the baseline level.
FIG. 2. Kaplan-Meier estimate of clearance of (A) HBV DNA, (B) HBeAg,
and (C) both HBV DNA and HBeAg during the initial 6 months retreatment
(solid line) or the observation period in the control group (dashed line) and
the 6 months of posterior follow-up.
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clearance (Table 2). This consisted of regression of the portal
and periportal inflammation and of the piecemeal necrosis
although the difference was not statistically significant. There
was no change in the degree of liver fibrosis. In most of the
cases, the necroinflammatory activity worsened in nonre-
sponders. In the final biopsies, the necroinflammatory activ-
ity was significantly lower (P 5 .012) in sustained responders
compared with nonresponders (Table 2).
Side effects consisted of a transient flu-like syndrome with
fever and myalgia that was seen in most of the patients in the
retreatment group during the first IFN-a injections. Around
30% of the patients reported mild to moderate anorexia,
fatigue (44%), and arthralgia (37%). Other events, such as
depression and hair loss were seen in 11% of the patients;
variceal bleeding was not observed in any patient. In all cases
the adverse effects attributed to IFN-a were reversible follow-
ing dose modification or cessation of therapy. The correspond-
ing occurrence of these events varied from 3% to 10% in the
untreated controls. Liver disease decompensation was ob-
served in 1/3 (33%) of the retreated cirrhotic patients that
required dose-reduction. One noncirrhotic patient required
dose-reduction because of abdominal pain. Finally, these 2
patients and another cirrhotic patient who developed hepato-
cellular carcinoma discontinued retreatment.
In the univariate analysis to assess the predictive factors of
response to IFN-a retreatment, sustained responders tended
to be younger, to have higher pretreatment ALT values, and
lower HBV DNA concentrations but the differences were not
statistically significant (data not shown). Among retreated
patients, 6/27 (22%) had received less than 432 MU total dose
of IFN-a in the previous cycle; this dose corresponds to at
least 9 MU 3 times per week for 16 weeks. Three out of six
(50%) patients having received less than 432 MU total dose of
IFN-a in the previous cycle showed a sustained response to
IFN-a retreatment compared with 6/21 (29%) patients who
had received at least 432 MU total dose of IFN-a in the
previous cycle (P 5 .37 by Fisher’s exact test). Among the 3
untreated controls who responded, 1/10 (10%) had received
less than, and 2/20 (10%) equal to or higher than, 432 MU
total dose of IFN-a in the previous cycle (P not significant).
None of the baseline features were associated with response
by Cox’s regression analysis (data not shown).
DISCUSSION
In this randomized controlled trial we have investigated
whether retreatment for 6 months with 9 MU of IFN-a-2a is
efficacious in HBeAg and HBV DNA–positive patients with
chronic hepatitis who did not respond to a previous course of
appropriate IFN-a treatment. We found that a sustained
clearance of these markers occurred significantly more fre-
quently in the retreated patients compared with the unre-
treated controls (33% vs. 10%). In addition, two-thirds of the
sustained responders to retreatment had seroconverted to
anti-HBe by the end of the 6-month post-treatment follow-
up. Furthermore, 5/9 sustained responders to retreatment
had normalized their ALT values, and a regression to normal
or near normal histology was observed in 3 of these patients.
A significant response was achieved only at the end of
follow-up, but not at the end of the treatment. The reason for
this behavior is not clear although there are several possible
explanations. Thus, serum HBV DNA concentrations de-
creased significantly when the basal and end-of-treatment
samples are compared. It has been proposed that a high HBV
DNA concentration may be associated with inefficient T-cell
reactivity against HBV.16,17 Thus, a decrease in HBV DNA
concentration may help to restore T-cell reactivity against
HBV during therapy with clearance of the virus during the
post-treatment follow-up. In addition, the possible role of
IFN-sensitive/resistant HBV variants in the response to treat-
ment should be taken into consideration. It has been showed
that mutant T-cell epitopes of the precore/core region may
diminish the antiviral T-cell responses against wild-type
HBV.18 Therefore, during therapy disappearance of T-cell
precore/core mutants may help to restore the T-cell responses
with subsequent clearance of HBV in the follow-up. However,
all these hypotheses require future research.
Nevertheless, the results are encouraging, because in a
previous pilot study using 1.5 to 5 MU of IFN-a daily for 16
weeks, the rate of sustained response to retreatment was
FIG. 3. Box-plot of the liver necroinflammatory score in the retreatment
and control groups before therapy (O basal) and at the end of the follow-up
period (h final).
TABLE 2. Comparison of the Liver Necroinflammatory Activity (grading)
and Fibrosis (staging) in Paired Basal and Final Biopsies in 30 Patients
Divided According to the Type of Response*
Responders
(n 5 10)†
Nonresponders
(n 5 20)‡
P§Basal Final Basal Final
Necroinflammatory
activity 4 (2-5.5) 3 (0.5-5) 4 (3-6) 5 (4.25-6) 0.012
Portal inflammation 2 (1-2) 1 (0.5-2) 2 (1.25-3) 2 (2-3) 0.001
Piecemeal necrosis 1 (0.5-2) 1 (0-1) 1 (0.25-2) 1.5 (1-2) 0.022
Lobular cytolysis 1 (0-2) 1 (0-1.5) 1 (0.25-2) 2 (1-2) 0.12
Fibrosis 1 (0.5-2.5) 1 (0-2.5) 2 (1-2) 2 (1-3) 0.13
*Results are expressed as median value and the 25th through 75th
percentile.
†Includes 7/9 who were sustained responders to retreatment with IFN-a
and the 3 who cleared HBV spontaneously in the control group.
‡Includes 8 nonresponders to retreatment and 12 in the control group.
§By Mann-Whitney’s U sustained responders vs. nonresponders in final
biopsies.
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11%.11 In the present study, the administration of higher
doses (9 MU, 3 times per week) during 6 months has made it
possible to achieve a higher rate of sustained response (33%).
This is specially important because the size of the study
population had to be reduced because of the unavailability of
the planned number of patients in a reasonable time, even
though it was designed as a large European multicenter
prospective trial. Thus, only 62 of the planned 145 patients
were enrolled. In spite of this, this is the first randomized
controlled trial showing the efficacy of the retreatment of
chronic hepatitis B with IFN-a.
None of the sustained responders in the study lost HBsAg
after the first 1-year period. After a single course of IFN-a
treatment, the rate of HBsAg loss during the initial year may
vary from 10% to 22%.5,10,19,20 Most HBsAg responses occur
several years after HBeAg and HBV DNA clearance, ranging
from 11.6% after 5 years to 71% after 11 years.5,9,10 Whether
HBsAg clearance and seroconversion to anti-HBs are delayed
in long-term HBV carriers who respond to a second course of
treatment is unknown at present, and the clinical significance
needs to be re-assessed in the future.
Another important observation in this study is the tolerabil-
ity of the retreatment, in view of the high dose used and
duration, with side effects similar to those already reported
during IFN-a treatment. However, liver disease decompensa-
tion was observed in 1 of the 3 retreated cirrhotic patients and
another developed an hepatocellular carcinoma. The occur-
rence of decompensation was in accordance with the 28%
reported by Fattovich et al1 in tumor-free patients. These
issues should be considered when retreating patients with
HBV-related cirrhosis.
Finally, we have not identified baseline features that are
related to response to retreatment with IFN-a probably
because of the small sample size. This is in contrast to the
predictive pretreatment factors known to influence the re-
sponse to IFN-a therapy in IFN-naive patients with chronic
hepatitis B.19 However, another report based on individual
patient data showed that the treatment effect of IFN-a was
independent of such variables.21 This suggests that some
viremic patients with unrecognized clinical and/or virologic
characteristics,22 who do not respond to initial IFN-a treat-
ment, may benefit from IFN-a retreatment.11 Recently, the
use of the nucleoside analogs lamivudine23 and famciclovir24
has been introduced for the treatment of chronic hepatitis B
in different settings.2 Although lamivudine, the most promis-
ing agent, seems to be highly effective in most patients at the
start of therapy in naive patients23,25 and in previous nonre-
sponders to IFN-a,26 development of resistance by mutations
in the viral polymerase is a significant clinical problem
following administration of lamivudine25 or famciclovir.27
The combination of lamivudine and IFN-a does not seem to
improve the results of retreatment with IFN-a as recently
reported in a pilot study conducted in previous nonre-
sponders to IFN-a.26 In conclusion, the results of the present
study indicate that retreatment with IFN-a may be consid-
ered as a therapeutic option for viremic patients with chronic
HBeAg–positive hepatitis.
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APPENDIX
The following European centers and investigators have
participated in this randomized controlled trial (values in
parenthesis denote the number of patients recruited): Spain –
Fundacio´n Jime´nez Dı´az, Madrid (12): J.A. Quiroga, M.
Pardo, S. Artillo, O. Bosch, and V. Carren´o; Hospital Clı´nico
Universitario, Granada (9): A. Palacios, L. Rodrı´guez-Ramos,
and J. Salmero´n; Hospital General Universitario, Valencia (6):
R. Zapater and M. Diago. France – Hopital Beaujon, Clichy
(11): N. Boyer, P. Marcellin. Greece – Hippokration General
Hospital, Athens (9): Ch. Vogiatzi, Ch. Papaioannou, and S.
Hadziyannis; General Regional Hospital, Thessaloniki (6): A.
Papachristou and G.E. Kitis; Laiko Loimoxeis General Hospi-
tal, Athens (5): I. Delladetsima and I. Vafiadis; Ippokratio
Hospital, Thessaloniki (1): J. Agorastos. The Netherlands –
University Hospital Dijkzigt, Rotterdam (3): H.L.A. Janssen
and S.W. Schalm.
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